Colitis refers to inflammation of the colon and may be caused by infections, inflammatory bowel disease, ischemia, medications, or other conditions.
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
Cabozantinib plus metronomic temozolomide showed a 15% response rate and 28.5-month median progression-free survival in a phase 2 NET study. A separate analysis found cabozantinib cost-effective for pancreatic NETs, but not extrapancreatic NETs, in China and the U.S.
Researchers used machine learning to identify an antimicrobial peptide, LR, that reduced inflammation and improved gut barrier function in mouse ulcerative colitis. The peptide also reshaped the microbiome and outperformed 5-aminosalicylic acid and ciprofloxacin in the model.
Meta-analysis of 23 trials finds neoadjuvant chemoimmunotherapy achieved 66% major pathologic response in head and neck cancer patients compared to 18% for dual-agent and 6% for single-agent immunotherapy, though survival impact remains unclear.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
Phase 2 SWOG S1512 trial shows neoadjuvant pembrolizumab achieved 71% pathologic complete response in resectable desmoplastic melanoma with 3-year survival rates of 74% for relapse-free and 87% for overall survival.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07541261 |
A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia |
NOT_YET_RECRUITING | |
| NCT07196410 |
KAN-004 for Immune-Related Diarrhea or Colitis |
RECRUITING | PHASE1 |
| NCT07047339 |
Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis |
RECRUITING | PHASE2/PHASE3 |
| NCT07012395 |
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis |
RECRUITING | PHASE2 |
| NCT06424769 |
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management |
ENROLLING_BY_INVITATION | NA |
| NCT06223347 |
Improved and Simplified Staining Technique for Dysplasia Detection in Colitis |
RECRUITING | |
| NCT06206707 |
FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis |
RECRUITING | NA |
| NCT06074874 |
Intestinal Biomarker Analysis After ECP for ICI Colitis |
COMPLETED | |
| NCT05947669 |
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis |
RECRUITING | PHASE3 |
| NCT05918562 |
Efficacy of a Low Fiber Diet for Pediatric Colonoscopy Prep |
UNKNOWN | NA |
